Zoetis (ZTS) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035

Vaccines, Medicines, Diagnostics, Parasiticides

Zoetis Inc. is a leading animal health company that develops, manufactures, and commercializes a wide range of innovative medicines, vaccines, and diagnostic products to improve the health and well-being of animals.

The company's product portfolio spans across multiple species, including livestock such as cattle, swine, poultry, fish, and sheep, as well as companion animals like dogs, cats, and horses. Its products cater to various health needs, including parasiticides, vaccines, dermatology, anti-infectives, and medicated feed additives.

Zoetis also offers a comprehensive range of animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors. Additionally, the company provides non-pharmaceutical products, such as nutritionals, as well as innovative solutions in biodevices, genetic tests, and precision animal health.

The company's products and services are designed to meet the needs of veterinarians, livestock producers, and pet owners. Zoetis has also formed strategic collaborations, such as its partnership with Blacksmith Medicines, Inc., to discover and develop novel antibiotics for animal health.

With a rich history dating back to 1952, Zoetis Inc. is headquartered in Parsippany, New Jersey, and continues to drive innovation and advancements in animal health. You can learn more about the company and its mission at https://www.zoetis.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Zoetis (ZTS) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Zoetis (ZTS) - Stock Price & Dividends

ZTS Stock Overview

Market Cap in USD 80,664m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2013-02-01

ZTS Stock Ratings

Growth 5y 30.7
Fundamental 89.1
Dividend 7.68
Rel. Performance vs Sector -0.94
Analysts 4.35/5
Fair Price Momentum 181.79 USD
Fair Price DCF 105.12 USD

ZTS Dividends

Yield 12m 0.94%
Yield on Cost 5y 1.48%
Dividends CAGR 5y 17.99%
Payout Consistency 100.0%

ZTS Growth Ratios

Growth 12m 2.16%
Growth Correlation 12m -7%
Growth Correlation 3m 42%
CAGR 5y 9.39%
CAGR/Mean DD 5y 0.57
Sharpe Ratio 12m -0.12
Alpha vs SP500 12m -24.90
Beta vs SP500 5y weekly 1.03
ValueRay RSI 35.90
Volatility GJR Garch 1y 26.58%
Price / SMA 50 3.14%
Price / SMA 200 -3.4%
Current Volume 1369.3k
Average Volume 20d 2190.6k

External Links for ZTS Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of ZTS stocks?
As of June 18, 2024, the stock is trading at USD 170.90 with a total of 1,369,312 shares traded.
Over the past week, the price has changed by -4.43%, over one month by -1.82%, over three months by +0.41% and over the past year by +1.07%.
What are the forecast for ZTS stock price target?
According to ValueRays Forecast Model, ZTS Zoetis will be worth about 201.9 in June 2025. The stock is currently trading at 170.90. This means that the stock has a potential upside of +18.12%.
Issuer Forecast Upside
Wallstreet Target Price 213.7 25.0
Analysts Target Price 222.8 30.4
ValueRay Target Price 201.9 18.1

The History and Evolution of Zoetis Inc

Zoetis Inc, recognized under the ticker ZTS on the New York Stock Exchange, marks its roots back to a division of Pfizer, the global pharmaceutical giant. Officially spun off from Pfizer in 2013, Zoetis quickly positioned itself as a leading force in the animal health industry. The company's journey from a segment of a larger entity to a standalone powerhouse illustrates its resilience and capability to innovate.

Core Business Insights

Zoetis Inc is predominantly known for its focus on animal health products and services. The company specializes in developing, manufacturing, and marketing a comprehensive range of medicines and vaccines for pets and livestock. Its core business revolves around four main categories: Companion Animal Products, Livestock Products, Diagnostics, and Genetics. The emphasis on innovation allows Zoetis to maintain a strong presence in both established and emerging markets, catering to a broad spectrum of animal health needs.

Exploring the Side Businesses

Beyond its primary focus, Zoetis also explores side businesses that complement its main operations. This includes investments in precision animal farming technology and collaborations aimed at environmental sustainability within the sector. Through such endeavors, Zoetis not only broadens its impact but also ensures a holistic approach to animal health and welfare.

Current Market Status

As of the current market conditions, Zoetis continues to exhibit strong performance and growth potential. The company's strategic initiatives, such as expanding its product portfolio and geographical presence, have solidified its status as a leader in the animal health sector. Furthermore, Zoetis's commitment to research and development positions it well to navigate future challenges and opportunities. The consistent pursuit of excellence and a customer-centric approach underpins Zoetis's market resilience and outlook for sustained success.